Event Videos

PPT Downloads|| HEPATICON 2017 Videos



Watch inaugural video here, all videos here






On Saturday, the 25th of March, Children’s Liver Foundation in association with Indian Academy of Pediatrics, Mumbai organized their 5th collaborative meeting “Hepaticon 2017” a meeting on a single theme – “Wilson disease - Bench to the bedside” at Nehru Centre in Worli. The meeting was endorsed by Indian Association for Study of the Liver (INASL) and Movement Disorders Society of India (MDSI). Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in various organs of the body, most commonly the liver and the brain. The interesting and yet challenging aspect of this disease is its myriad manifestations where patients may be as young as 3 years old to the adult 55 years old. The meeting served a much needed collaboration between Neurologists, Gastroenterologists and Pediatricians' experience of this disease whose manifestations may be complex and often get diagnosed late, misdiagnosed or even over-diagnosed. The conference was first of its kind where doctors from different specialties from different parts of India came and shared their perspectives and encounters with different presentations and outcomes of the disease. Besides our local faculty, we had institutions like AIIMS, Delhi, NIMHANS, Bengaluru, PGI Chandigarh, SGPGI, Lucknow, CMC Vellore, Apollo Hospitals Delhi and Chennai and ILBS Delhi and many others participate in the meeting. The highlight of the inaugural function was a poem recited by Janice – a patient of Wilson’s on her life journey from being a bed ridden patient to a normal life she leads now. Ojas – another patient of Wilson disease recounted his journey from presenting with acute liver failure to undergoing a liver transplant and now being well rehabilitated and pursuing undergraduation in Medicine. Dr Aabha Nagral of Children’s Liver Foundation, Dr Bela Verma from IAP, Mumbai, Dr RK Dhiman from INASL and Dr Pettarusp Wadia from MDSI inaugurated the meeting. The talks and presentations on this day helped us understand and opened our minds to the unlimited variables of how Wilson's disease can present. We were given interesting information about copper, how it can be beneficial in health and also how it's excess can damage our body. Through case presentations, management of different presentations was discussed and we learnt how differently the neurologists and gastroenterologists treat Wilson's. There was a healthy discussion and debate on whether the disease should be treated with zinc or penicillamine or a combination of both. Genetics, developmental pediatrics, speech therapy, physiotherapy, diet and psychology related issues of the disease were also discussed in great detail to emphasize the need for a more holistic approach. The audience was enlightened about the 600 different mutations Wilson's can have and the importance of family screening. The role of development, management of behavioural changes and counseling was emphasized by developmental Pediatrician and IAP President - Dr Samir Dalwai as being as important as taking medications. He proposed a collaborative study between CLF and IAP, Mumbai on studying the developmental and behavioural issues in these patients where very little work has been done. Light was thrown upon the unfortunate disappearance of the very important drug Penicillamine from the market, how much inconvenience it had caused the patients and how doctors and medical societies worked hard to get the medicine back into the market. In spite of the conference being on such a focused topic, the interaction amongst the delegates and faculty kept every person glued in for the 10 hours of the day that the meeting lasted with a resolve to develop guidelines in managing this disease with an Indian perspective.
The powerpoint presentations and video-recorded proceedings of the meeting will be available by 30th April 2017 on the website of Children’s Liver Foundation i.e.www.childrenliverindia.org

https://www.ncbi.nlm.nih.gov/pubmed/27504812

Valentino PL, Wiggins S, Harney S, Raza R, Lee CK, Jonas MM. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):603-609.

Abstract

OBJECTIVES:

Data regarding pediatric primary sclerosing cholangitis (PSC) natural history are limited. We describe a large pediatricPSC cohort with longitudinal follow-up.

METHODS:

The present study records review of pediatric patients with PSC diagnosed between 1984 and 2014.

RESULTS:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/26910645

Prytula A, Vandekerckhove K, Raes A, De Wolf D, Dehoorne J, Vande Walle J, De Bruyne R. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):616-623.

Abstract

BACKGROUND:

The aim of the study was to analyze the incidence of hypertension in pediatric liver transplantation (LT) recipients using ambulatory blood pressure measurements (ABPM) and to identify factors associated with hypertension. We also investigated whether hypertension or tacrolimus predose concentration (TAC C0) was associated with increased left ventricular (LV) wall thickness.

PATIENTS AND METHODS:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/27312946

van Zutphen T, Ciapaite J, Bloks VW, Ackereley C, Gerding A, Jurdzinski A, de Moraes RA, Zhang L, Wolters JC, Bischoff R, Wanders RJ, Houten SM, Bronte-Tinkew D, Shatseva T, Lewis GF, Groen AK, Reijngoud DJ, Bakker BM, Jonker JW, Kim PK, Bandsma RH. J Hepatol. 2016 Dec;65(6):1198-1208. doi: 10.1016/j.jhep.2016.05.046

Abstract

BACKGROUND & AIMS:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/27663215

Usatin D, Fernandes M, Allen IE, Perito ER, Ostroff J, Heyman MB. J Pediatr. 2016 Dec;179:160-165.e3. doi: 10.1016/j.jpeds.2016.08.046.

Abstract

OBJECTIVES:

To systematically review risks and summarize reported complication rates associated with the performance of endoscopic retrograde cholangiopancreatography (ERCP) in children during the past 2 decades.

STUDY DESIGN:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/27417217

Lin YC, Chang PF, Lin HF, Liu K, Chang MH, Ni YH. J Hepatol. 2016 Dec;65(6):1209-1216. doi: 10.1016/j.jhep.2016.06.029.

Abstract

BACKGROUND & AIMS:

Autophagy has been shown to be crucial in the regulation of the intracellular lipid stores in hepatocytes. We hypothesize that immunity-related GTPase family M (IRGM) gene (an autophagy-related gene) variants confer the susceptibility to non-alcoholic fatty liver disease (NAFLD) development.

METHODS:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/27749391

Lungren MP, Lindquester WS, Seidel FG, Kothary N, Monroe EJ, Shivaram G, Gill AE, Hawkins MC. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):e147-e151

Abstract

OBJECTIVES:

The aim of the study was to describe and assess the technical success and safety of ultrasound-guided liver biopsy with gelatin sponge pledget tract embolization technique in infants <10 kg across 3 tertiary pediatric hospitals.

MATERIALS AND METHODS:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/27429423

Thébaut A, Nemeth A, Le Mouhaër J, Scheenstra R, Baumann U, Koot B, Gottrand F, Houwen R, Monard L, de Micheaux SL, Habes D, Jacquemin E. J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):610-615.

Abstract

OBJECTIVES:

D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe to provide an orally bioavailable source of vitamin E in children with cholestasis. The aim was to analyze the safety/efficacy of Vedrop in a large group of children with chronic cholestasis.

METHODS:

Published on: 
Dec-2016

https://www.ncbi.nlm.nih.gov/pubmed/27569726

Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E; NASH CRN.

Gastroenterology. 2016 Dec;151(6):1141-1154.e9. doi: 10.1053/j.gastro.2016.08.027.

Abstract

BACKGROUND & AIMS:

No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD.

METHODS:

Published on: 
Dec-2016

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: